Verrica Pharmaceuticals Inc. (VRCA) — 8-K Filings

8-K Filings (32)

• Verrica Pharmaceuticals Reports Director and Officer Changes — Dec 30, 2025 Risk: medium
  Verrica Pharmaceuticals Inc. announced on December 23, 2025, changes related to its board of directors and executive compensation. Specifically, the company rep
• 8-K Filing — Nov 24, 2025
• Verrica Pharmaceuticals Files 8-K on Financials — Nov 14, 2025 Risk: low
  Verrica Pharmaceuticals Inc. filed an 8-K on November 14, 2025, reporting on its results of operations and financial condition. The filing includes financial st
• Verrica Pharmaceuticals Files 8-K — Aug 12, 2025 Risk: low
  Verrica Pharmaceuticals Inc. filed an 8-K on August 12, 2025, reporting on events as of August 8, 2025. The filing pertains to results of operations, financial
• Verrica Pharmaceuticals Faces Delisting Notice — Jul 30, 2025 Risk: high
  Verrica Pharmaceuticals Inc. filed an 8-K on July 30, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of Jul
• Verrica Pharma Files 8-K on Security Holder Rights — Jul 23, 2025 Risk: medium
  Verrica Pharmaceuticals Inc. filed an 8-K on July 23, 2025, reporting material modifications to the rights of security holders and financial statements/exhibits
• Verrica Pharmaceuticals Files 8-K — Jul 1, 2025 Risk: medium
  On June 27, 2025, Verrica Pharmaceuticals Inc. entered into a material definitive agreement. The filing also includes Regulation FD Disclosure and Financial Sta
• Verrica Pharmaceuticals Enters Material Definitive Agreement — Jun 12, 2025 Risk: medium
  Verrica Pharmaceuticals Inc. entered into a material definitive agreement on June 10, 2025. The filing does not disclose specific details of the agreement, such
• Verrica Pharmaceuticals Files 8-K on Shareholder Votes — Jun 5, 2025 Risk: low
  Verrica Pharmaceuticals Inc. filed an 8-K on June 5, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's co
• Verrica Pharmaceuticals Files 8-K on Financials — May 13, 2025 Risk: low
  Verrica Pharmaceuticals Inc. filed an 8-K on May 13, 2025, reporting on its results of operations and financial condition. The filing includes financial stateme
• Verrica Pharma Announces Board & Executive Changes — Apr 25, 2025 Risk: medium
  Verrica Pharmaceuticals Inc. announced on April 22, 2025, changes in its board of directors and executive compensation arrangements. The filing details the depa
• Verrica Pharma Reports Director Changes & Compensation Updates — Apr 2, 2025 Risk: medium
  Verrica Pharmaceuticals Inc. announced on March 31, 2025, changes in its board of directors and executive compensation arrangements. The filing details the depa
• Verrica Pharmaceuticals Files 8-K on Financials — Mar 11, 2025 Risk: low
  Verrica Pharmaceuticals Inc. filed an 8-K on March 11, 2025, reporting on its results of operations and financial condition. The filing includes financial state
• Verrica Pharmaceuticals Enters Material Definitive Agreement — Feb 21, 2025 Risk: medium
  On February 18, 2025, Verrica Pharmaceuticals Inc. entered into a Material Definitive Agreement. The filing does not provide specific details about the agreemen
• Verrica Pharmaceuticals Faces Nasdaq Delisting Notice — Jan 30, 2025 Risk: high
  Verrica Pharmaceuticals Inc. announced on January 24, 2025, that it received a notice from The Nasdaq Stock Market indicating a failure to meet continued listin
• Verrica Pharma Relocates HQ, Hints at Officer/Director Changes — Dec 9, 2024 Risk: medium
  Verrica Pharmaceuticals Inc. announced on December 4, 2024, a change in its principal executive offices to 44 W. Gay St., Suite 400, West Chester, PA 19380. Thi
• Verrica Pharmaceuticals Enters Material Definitive Agreement — Nov 21, 2024 Risk: medium
  On November 20, 2024, Verrica Pharmaceuticals Inc. entered into a material definitive agreement. The company also reported other events and filed financial stat
• Verrica Pharma Files 8-K — Nov 20, 2024 Risk: low
  Verrica Pharmaceuticals Inc. filed an 8-K on November 20, 2024, to report other events and financial statements. The filing details the company's principal exec
• Verrica Pharma Files 8-K on Financials and Personnel — Nov 4, 2024 Risk: medium
  Verrica Pharmaceuticals Inc. filed an 8-K on November 4, 2024, reporting on results of operations and financial condition, as well as changes in directors and o
• Verrica Pharmaceuticals Faces Nasdaq Delisting Warning — Oct 8, 2024 Risk: high
  Verrica Pharmaceuticals Inc. announced on October 2, 2024, that it received a notice from The Nasdaq Stock Market LLC regarding its failure to meet the minimum
• Verrica Pharma Reports Exit/Disposal Costs — Oct 1, 2024 Risk: medium
  Verrica Pharmaceuticals Inc. filed an 8-K on October 1, 2024, to report on cost associated with exit or disposal activities. The filing does not contain specifi
• Verrica Pharmaceuticals Announces Executive and Board Changes — Sep 27, 2024 Risk: medium
  Verrica Pharmaceuticals Inc. announced on September 23, 2024, changes in its executive and director roles. The company appointed Dr. Robert L. W. Smith as Chief
• Verrica Pharma Shuffles Leadership, Adds Directors — Sep 6, 2024 Risk: medium
  Verrica Pharmaceuticals Inc. announced on August 30, 2024, the departure of its Chief Medical Officer, Dr. Robert W. Buck, effective the same date. The company
• Verrica Pharma: CMO Departs, New Directors Elected — Aug 27, 2024 Risk: medium
  Verrica Pharmaceuticals Inc. announced on August 21, 2024, the departure of its Chief Medical Officer, Dr. Robert L. Armstrong. The company also reported the el
• Verrica Pharmaceuticals Files 8-K on Financials — Aug 14, 2024 Risk: low
  Verrica Pharmaceuticals Inc. filed an 8-K on August 14, 2024, reporting on its results of operations and financial condition, along with Regulation FD disclosur
• Verrica Pharmaceuticals Enters Material Definitive Agreement — Aug 5, 2024 Risk: medium
  On August 2, 2024, Verrica Pharmaceuticals Inc. entered into a Material Definitive Agreement. The filing does not disclose the specific details or parties invol
• Verrica Pharmaceuticals Enters Material Definitive Agreement — Jun 28, 2024 Risk: medium
  On June 26, 2024, Verrica Pharmaceuticals Inc. entered into a Material Definitive Agreement. The filing does not disclose the specific details of this agreement
• Verrica Pharmaceuticals Files 8-K on Security Holder Votes — Jun 10, 2024 Risk: low
  Verrica Pharmaceuticals Inc. filed an 8-K on June 10, 2024, reporting on matters submitted to a vote of its security holders as of June 6, 2024. The filing deta
• Verrica Pharmaceuticals Enters Material Agreement, Discloses Equity Sales — May 15, 2024 Risk: medium
  Verrica Pharmaceuticals Inc. announced on May 14, 2024, that it entered into a Material Definitive Agreement. The company also disclosed unregistered sales of e
• Verrica Pharmaceuticals Files 8-K on Financials — May 13, 2024 Risk: low
  Verrica Pharmaceuticals Inc. filed an 8-K on May 13, 2024, reporting on its results of operations and financial condition. The filing includes financial stateme
• Verrica Pharma Files 8-K on Financial Condition — Feb 29, 2024 Risk: low
  Verrica Pharmaceuticals Inc. filed an 8-K on February 29, 2024, to report on its results of operations and financial condition. The filing, under SEC File Numbe
• Verrica Pharma Changes HQ Address in West Chester, PA — Jan 8, 2024
  Verrica Pharmaceuticals Inc. filed an 8-K on January 8, 2024, to report a change in its principal executive offices from 10 North High Street, Suite 200, West C

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX